MK-458 (HPMC) is a new, potent, long-acting anf highly-selective D2 dopamine receptor agonist which, in a 30-day open trial, demonstrated marked anti-parkinson efficacy. We propose a 6-month, open treatment study to ascertain the long-term efficacy, tolerability, and safety of MK- 458 as a substitution for sinemet in fluctuating parkinsonian patients.
Showing the most recent 10 out of 674 publications